Health care professionals should be aware that FDA found no increased risk of SI/B with the use of GLP-1 RA medications and is requesting the removal of this Warning and Precaution from the prescribing information for the GLP-1 RA medications (Saxenda, Wegovy, and Zepbound) that include such language
Engage in a mix of aerobic activities, strength training, and flexibility exercises
Although transient elevations in liver metabolic enzymes occurred during treatment, subsequent abdominal ultrasound examinations revealed no hepatic abnormalities
The results showed that tirzepatide significantly reduced UACR at Week 40/42 compared to pooled comparators, with the following reductions: 19.3% for 5 mg, 22.0% for 10 mg, and 26.3% for 15 mg
The study's findings revealed a marked increase in GLP-1RA use among Americans, both with and without a reported history of diabetes, largely driven by increased semaglutide use following its approval for weight management
Choosing the Right GLP-1 Medication for You The choice between tirzepatide and semaglutide depends on your personal health needs, goals, and medical history
